Monday, December 30, 2019

AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer

AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer The drug is now the only approved medicine in biomarker-selected patients with advanced pancreatic cancer.

from Moneycontrol Business News https://ift.tt/35awRrv

No comments:

Post a Comment

Paras Defence shares soar 10% as Q2 net profit jumps 50% to Rs 14 crore

Paras Defence and Space Technologies shares surged following strong September quarter results, with net profit jumping 50% and revenue climb...